中药肝复康对肝星状细胞mTOR/P70S6K信号通路的干预作用

doi:10.3969/j.issn.1672-5069.2012.01.012

Abstract

Abstract: Objective To study the effect of blood serum supplemented with Ganfukang compound,a traditional Chinese herb medicine,on the mTOR/P70S6K signal pathway in hepatic stellate cells（HSCs）.Methods HSC-T6 stimulated by acetaldehyde were incubated with blood serum of Ganfukang compound.The expressions of collagen-Ⅰ,Ⅲ,mTOR and P70S6K in each group were analyzed by RT-PCR. Results HSCs exhibited a low mRNA level of collagen-Ⅰ,Ⅲ,mTOR and P70S6K in the control group,whereas they were remarkably increased in the model group（P<0.01 or P<0.05）,and the expression of them were downregulated after treated with blood serum of Ganfukang compound（P<0.01）.Conclusions mTOR/P70S6K signal pathway play an important roles in HSCs activation,and the anti-fibrosis effects of Ganfukang are related to the inhibition of mTOR/P70S6K signal pathway.

Key words: Hepatic stellate cells, Ganfukang, mTOR/P70S6K signal pathway

Zhang Kun, Jiang Miaona, Zhang Caihua, et al. Effect of Chinese traditional medicine Ganfukang on the mTOR/P70S6K signal pathway in liver stellate cells[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(1): 24-25.

References

[1] Wynn TA.Cellular and molecular mechanisms of fibrosis.J Pathol,2008,214（2）:199-210.
[2] Gressner AM,Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med,2006,10（1）:76-99.
[3] Zheng Y,Collins SL,Lutz MA,et al.A role for mammalian target of rapamycin in regulating T cell activation versus anergy.J Immunol,2007,178:2163-2170.
[4] Patsenker E.Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol,2011,doi:10.1016/j.jhep.2010.10.044.
[5] 彭贵主,吴波,单人锋,等. mTOR/P70S6K信号通路在肝细胞肝癌中的表达及临床意义.世界华人消化杂志,2008,16（29）:3279-3282.
[6] 杨妙芳,许小兵,吴文娟,等. 核糖体S6激酶对肝星状细胞内胶原表达的调控. 第四军医大学学报,2008,29（19）:1753-1756.
[7] 车颖,徐婷婷,姜妙娜,等. 肝复康胶囊对实验性肝纤维化大鼠肝细胞的保护作用. 中药材,2004,27（6）:428-429.
[8] 车颖,徐婷婷,姜妙娜,等.肝复康抗大鼠肝纤维化的实验研究.中国中药杂志,2004,29（6）:599-600.
[9] Xu TT,Jiang MN,Li C.Effect of Chinese traditional compound,
Gan-fu-kang,on CCl4-induced liver fibrosis in rats and its probable molecular mechanisms.Hepatol Res,2007,37:221-229.
[10] Lou JL,Jiang MN,Li C,et al. Herb medicine Gan-fu-kang attenuates liver injury in a rat fibrotic model. J Ethnopharmacol,2010,128:131-138.
[11] 张彩华,崔晓栋,姜妙娜,等. 肝复康不同浓度含药血清对肝星状细胞Ⅰ、Ⅲ型胶原及细胞基质的影响. 中国组织工程研究与临床康复,2008,12（33）:6496-6499.
[12] Sonoyama T,Tamura N,Miyashita K,et al.Inhibition of hepatic damage and liver fibrosis by brain natriuretic peptide. FEBS Lett,2009,583（12）:2067-2070.
[13] Rao RD,Buekner JC,Sarkaria JN.Mammalian target of rapamyein（mTOR） inhibitors as anticancer agents.Curr Caneer Drug Targets,2004:4:621-635.
[14] Buck M,Chojkier M A.Ribosomal S-6 Kinase-mediated signal to C/EBP-b is critical for the development of liver fibrosis.PLoS ONE,2007,2（12）:e1372.
[15] Jamison JT,Kayali F,Rudolph J,et al.Persistent redistribution of poly- adenylated mRNAs correlates with translation arrest and cell death following global brain ischemia and reperfusion.Neuroseience,2008,154:504-520.

Effect of Chinese traditional medicine Ganfukang on the mTOR/P70S6K signal pathway in liver stellate cells

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 11

Recommended Articles

Metrics

Comments

[1]	Zhou Liyun, Li Xiaotian, Li Li. 1,25（OH）₂D₃ inhibits hepatic fibrosis by regulating miR-146a levels in vitro and in vivo [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 333-336.
[2]	Zhang Kun，Hu Hai，Zhang Yuan，et al.. Changes of CTGF，fibronectin and integrin mRNA levels in Gan-fu-kang，a herbal medicine-intervened rat hepatic stellate cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 153-156.
[3]	Tong Yanyan, Li Guangming, Deng Yilin, et al. Inhibition of primary cultured hepatic stellate cell activation by phenylarsine oxide in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 413-417.
[4]	Shi Feng, Wang Nongrong. Roles of profibrogenic factors in liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 505-508.
[5]	Hu Ye, Zhang Guo. Anti-hepatic fibrosis therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 8-11.
[6]	Ge Wensong，Fang Jiangao， Li Guangming. Inhibition of small interfering RNA targeting high mobility group box chromosomal protein 1 on collagen type Ⅰand Ⅲ in hepatic stellate cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 340-343.
[7]	Wang Jun，Li Guangming，Tong Yanyan，et al.. Mechanism of 12-4-Y，a novel isoquinoline compound， on apoptosis of activated hepatic stellate cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 344-347.
[8]	Li Xin, Zhu Ying. Signaling pathways in hepatic fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 101-104.
[9]	Hao Shuli, Zhang Jiyuan, Jin Lei. Plasma IL-21 levels in patients with alcoholic liver diseases and the effects of recombinant IL-21 on proliferation and activation of LX-2 hepatic stellate cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 18-21.
[10]	Peng Meijuan, Hao Chunqiu, Zhang Ye, et al.. Observation of inhibition of connective tissue growth factor by siRNA on the changes of proliferation and activation of hepatic stellate cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(5): 430-433.
[11]	GE Wensong，WU Jiangxin，CHEN Yinwei，et al.. Effect of interfering RNA targeting β-Catenin on the proliferation and apoptosis of hepatic stellate cells in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(2): 91-94.